Development
- A World Away
-
Finding solutions for the neglected tropical diseases that affect one billion people worldwide requires not only a commitment to conduct sorely needed research, but also a rethinking of drug development’s value proposition.
- Biotechs and the Public Market
-
After a disastrous first half of 2008, the question becomes: Are IPOs still fueling the biotech industry?
- Europe: The Hard Cell
-
Stem cell research receives official funding from the European Parliament. But the opportunities this presents for EU researchers remain complex and controversial.
- Advanced Planning
-
Although the European and American approaches to pharmaceutical risk management differ slightly, both share the common objective of ensuring patient safety for marketed products.
- Streamlining Safety Data
-
With electronic data collection becoming more mainstream, clinical trialists are now looking to incorporate safety data into the electronic mix as well.
- Image Awareness
-
Radiological biomarkers hold the potential to be a positive force in pharmaceutical research, but the adoption of imaging techniques as a useful tool for drug development has been slow to materialize.
- Control Mechanism
-
A rapidly increasing rate of type 2 diabetes has researchers scrambling for new interventions to combat the chronic condition.
- BIOspeak
-
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO) and a former member of the U.S. Congress, discusses the most critical policy challenges facing the industry today.
- Asian Migration
-
Access to patients, lower costs and increased efficiencies are leading to an explosion in the amount of clinical research being conducted in Asia.
- Joining Forces
-
Global partnerships enable big pharma to streamline drug development and refocus their efforts on core competencies.
Web Exclusives
- Statistical Advantage
-
Gary Shorter, director of biostatistics for Quintiles, talks to Envisage editor Adam Istas about the growing importance of incorporating biostatistical analysis into all stages of drug development.
- Measure for Measure
-
A proposed Health Care Comparative Effectiveness Research Institute in the United States may force the biopharmaceutical industry to emphasize patient outcomes and quality of life issues when developing a new medicinal product.